Work

Correction to: Outcomes based on plasma biomarkers in METEOR, a randomized phase 3 trial of cabozantinib vs everolimus in advanced renal cell carcinoma

Year: 2021

Type: erratum

Source: BMC Cancer

DOI: 10.1186/s12885-021-08693-9

Authors: Thomas Powles, Toni K. Choueiri, Robert J. Motzer, Eric Jonasch, Sumanta Pal, Nizar M. Tannir, Sabina Signoretti, Rajesh Kaldate, Christian Scheffold, Evelyn Wang, Dana T. Aftab, Bernard Escudier, Daniel J. George

Institutions: Queen Mary University of London, Barts Cancer Institute, Dana-Farber Cancer Institute, Memorial Sloan Kettering Cancer Center, The University of Texas MD Anderson Cancer Center, City Of Hope National Medical Center, Brigham and Women's Hospital, Exelixis (United States), Institut Gustave Roussy, Duke University, Duke Cancer Institute

Language: English

Topic: Renal cell carcinoma treatment

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $2,570

Funders: Bristol-Myers Squibb, Pfizer, AstraZeneca, Exelixis, Incyte, Eisai, Astellas Pharma, Ipsen

OpenAlex ID: W4231554106

Cites: 1

Cited by: 2

Related to: 10